Belite Bio
San Diego
About Belite Bio
Belite Bio focused on first-in-class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic age-related macular degeneration, stargardt disease, and nonalcoholic steatohepatitis. They develop anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Their technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease, and diabetes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $588.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:BLTE
- Website: belitebio.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/belite-bio-24819 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.